FORM 10-Q
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
|
|
|
þ |
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended December 27, 2008
OR
|
|
|
o |
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from
to
Commission File Number: 1-5129
MOOG INC.
(Exact name of registrant as specified in its charter)
|
|
|
New York State
|
|
16-0757636 |
(State or other jurisdiction of incorporation or organization)
|
|
(I.R.S. Employer Identification No.) |
|
|
|
East Aurora, New York
|
|
14052-0018 |
(Address of principal executive offices)
|
|
(Zip Code) |
Telephone number including area code: (716) 652-2000
Former name, former address and former fiscal year, if changed since last report.
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes þ No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer þ | Accelerated filer o | Non-accelerated filer o (Do not check if a smaller reporting company) | Smaller reporting company o |
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the
Exchange Act). Yes o No þ
The number of shares outstanding of each class of common stock as of January 29, 2009 was:
Class A common stock, $1.00 par value 38,506,449 shares
Class B common stock, $1.00 par value 4,039,768 shares
MOOG
INC.
QUARTERLY REPORT ON FORM 10-Q
TABLE OF CONTENTS
2
PART I FINANCIAL INFORMATION
Item 1. Financial Statements.
MOOG
INC.
Consolidated Condensed Balance Sheets
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
December 27, |
|
|
September 27, |
|
(dollars in thousands) |
|
2008 |
|
|
2008 |
|
|
ASSETS |
|
|
|
|
|
|
|
|
CURRENT ASSETS |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
118,417 |
|
|
$ |
86,814 |
|
Receivables |
|
|
484,748 |
|
|
|
517,361 |
|
Inventories |
|
|
425,366 |
|
|
|
408,295 |
|
Other current assets |
|
|
84,904 |
|
|
|
77,915 |
|
|
|
|
TOTAL CURRENT ASSETS |
|
|
1,113,435 |
|
|
|
1,090,385 |
|
PROPERTY, PLANT AND EQUIPMENT, net of accumulated
depreciation of $408,199 and $399,806 respectively |
|
|
428,889 |
|
|
|
428,120 |
|
GOODWILL |
|
|
557,155 |
|
|
|
560,735 |
|
INTANGIBLE ASSETS, net |
|
|
75,936 |
|
|
|
74,755 |
|
OTHER ASSETS |
|
|
80,115 |
|
|
|
73,252 |
|
|
|
|
TOTAL ASSETS |
|
$ |
2,255,530 |
|
|
$ |
2,227,247 |
|
|
LIABILITIES AND SHAREHOLDERS EQUITY |
|
|
|
|
|
|
|
|
CURRENT LIABILITIES |
|
|
|
|
|
|
|
|
Notes payable |
|
$ |
12,187 |
|
|
$ |
7,579 |
|
Current installments of long-term debt |
|
|
1,402 |
|
|
|
1,487 |
|
Accounts payable |
|
|
127,447 |
|
|
|
128,723 |
|
Customer advances |
|
|
42,224 |
|
|
|
41,507 |
|
Contract loss reserves |
|
|
21,781 |
|
|
|
20,536 |
|
Other accrued liabilities |
|
|
157,258 |
|
|
|
177,261 |
|
|
|
|
TOTAL CURRENT LIABILITIES |
|
|
362,299 |
|
|
|
377,093 |
|
LONG-TERM DEBT, excluding current installments |
|
|
|
|
|
|
|
|
Senior debt |
|
|
298,856 |
|
|
|
261,922 |
|
Senior subordinated notes |
|
|
400,068 |
|
|
|
400,072 |
|
LONG-TERM PENSION AND RETIREMENT OBLIGATIONS |
|
|
106,105 |
|
|
|
108,072 |
|
DEFERRED INCOME TAXES |
|
|
82,157 |
|
|
|
80,754 |
|
OTHER LONG-TERM LIABILITIES |
|
|
4,898 |
|
|
|
4,924 |
|
|
|
|
TOTAL LIABILITIES |
|
|
1,254,383 |
|
|
|
1,232,837 |
|
|
|
|
SHAREHOLDERS EQUITY |
|
|
|
|
|
|
|
|
Common stock |
|
|
48,605 |
|
|
|
48,605 |
|
Other shareholders equity |
|
|
952,542 |
|
|
|
945,805 |
|
|
|
|
TOTAL SHAREHOLDERS EQUITY |
|
|
1,001,147 |
|
|
|
994,410 |
|
|
|
|
TOTAL LIABILITIES AND SHAREHOLDERS EQUITY |
|
$ |
2,255,530 |
|
|
$ |
2,227,247 |
|
|
See accompanying Notes to Consolidated Condensed Financial Statements.
3
MOOG
INC.
Consolidated Condensed Statements of Earnings
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
December 27, |
|
|
December 29, |
|
(dollars in thousands, except per share data) |
|
2008 |
|
|
2007 |
|
|
NET SALES |
|
$ |
446,088 |
|
|
$ |
446,407 |
|
|
COST OF SALES |
|
|
308,240 |
|
|
|
298,777 |
|
|
|
|
|
GROSS PROFIT |
|
|
137,848 |
|
|
|
147,630 |
|
|
Research and development |
|
|
25,130 |
|
|
|
24,092 |
|
|
Selling, general and administrative |
|
|
69,199 |
|
|
|
71,282 |
|
|
Interest |
|
|
9,601 |
|
|
|
9,712 |
|
|
Equity in earnings of LTi and other |
|
|
(2,455 |
) |
|
|
114 |
|
|
|
|
|
EARNINGS BEFORE INCOME TAXES |
|
|
36,373 |
|
|
|
42,430 |
|
|
INCOME TAXES |
|
|
6,103 |
|
|
|
14,755 |
|
|
|
|
|
NET EARNINGS |
|
$ |
30,270 |
|
|
$ |
27,675 |
|
|
|
|
|
|
|
|
|
|
|
|
|
NET EARNINGS PER SHARE |
|
|
|
|
|
|
|
|
Basic |
|
$ |
.71 |
|
|
$ |
.65 |
|
|
Diluted |
|
$ |
.70 |
|
|
$ |
.64 |
|
|
|
|
|
|
|
|
|
|
|
|
|
AVERAGE COMMON SHARES OUTSTANDING |
|
|
|
|
|
|
|
|
Basic |
|
|
42,607,289 |
|
|
|
42,485,328 |
|
|
Diluted |
|
|
42,986,088 |
|
|
|
43,258,660 |
|
|
See accompanying Notes to Consolidated Condensed Financial Statements.
4
MOOG
INC.
Consolidated Condensed Statements of Cash Flows
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
December 27, |
|
|
December 29, |
|
(dollars in thousands) |
|
2008 |
|
|
2007 |
|
|
CASH FLOWS FROM OPERATING ACTIVITIES |
|
|
|
|
|
|
|
|
Net earnings |
|
$ |
30,270 |
|
|
$ |
27,675 |
|
Adjustments to reconcile net earnings to net cash provided (used)
by operating activities: |
|
|
|
|
|
|
|
|
Depreciation |
|
|
13,135 |
|
|
|
11,359 |
|
Amortization |
|
|
3,830 |
|
|
|
3,980 |
|
Provisions for non-cash losses on contracts, inventories and receivables |
|
|
12,814 |
|
|
|
4,594 |
|
Equity-based compensation expense |
|
|
2,589 |
|
|
|
1,628 |
|
Other |
|
|
(3,264 |
) |
|
|
(154 |
) |
Changes in assets and liabilities providing (using) cash, excluding the
effects of acquisitions: |
|
|
|
|
|
|
|
|
Receivables |
|
|
25,974 |
|
|
|
(30,476 |
) |
Inventories |
|
|
(23,966 |
) |
|
|
(18,022 |
) |
Accrued expenses |
|
|
(26,200 |
) |
|
|
(16,326 |
) |
Other assets and liabilities |
|
|
(2,633 |
) |
|
|
12,068 |
|
|
|
|
NET CASH PROVIDED (USED) BY OPERATING ACTIVITIES |
|
|
32,549 |
|
|
|
(3,674 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
CASH FLOWS FROM INVESTING ACTIVITIES |
|
|
|
|
|
|
|
|
Acquisitions of businesses, net of acquired cash |
|
|
(14,023 |
) |
|
|
(9,085 |
) |
Purchase of property, plant and equipment |
|
|
(20,498 |
) |
|
|
(25,091 |
) |
Other |
|
|
29 |
|
|
|
(1,298 |
) |
|
|
|
NET CASH USED BY INVESTING ACTIVITIES |
|
|
(34,492 |
) |
|
|
(35,474 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
CASH FLOWS FROM FINANCING ACTIVITIES |
|
|
|
|
|
|
|
|
Net proceeds from (repayments of) notes payable |
|
|
4,434 |
|
|
|
(2,585 |
) |
Net proceeds from revolving lines of credit |
|
|
37,500 |
|
|
|
42,295 |
|
Payments on long-term debt |
|
|
(287 |
) |
|
|
(270 |
) |
Excess tax benefits from equity-based payment arrangements |
|
|
43 |
|
|
|
586 |
|
Other |
|
|
(5,592 |
) |
|
|
(3,196 |
) |
|
|
|
NET CASH PROVIDED BY FINANCING ACTIVITIES |
|
|
36,098 |
|
|
|
36,830 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Effect of exchange rate changes on cash |
|
|
(2,552 |
) |
|
|
1,614 |
|
|
|
|
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS |
|
|
31,603 |
|
|
|
(704 |
) |
Cash and cash equivalents at beginning of period |
|
|
86,814 |
|
|
|
83,856 |
|
|
|
|
CASH AND CASH EQUIVALENTS AT END OF PERIOD |
|
$ |
118,417 |
|
|
$ |
83,152 |
|
|
|
|
|
|
|
|
|
|
|
|
|
CASH PAID FOR: |
|
|
|
|
|
|
|
|
Interest |
|
$ |
10,657 |
|
|
$ |
7,299 |
|
Income taxes, net of refunds |
|
|
4,012 |
|
|
|
8,117 |
|
|
See accompanying Notes to Consolidated Condensed Financial Statements.
5
MOOG inc.
Notes to Consolidated Condensed Financial Statements
Three Months Ended December 27, 2008
(Unaudited)
(dollars in thousands, except per share data)
Note 1 - Basis of Presentation
The accompanying unaudited consolidated condensed financial statements have been prepared by
management in accordance with U.S. generally accepted accounting principles for interim financial
information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion
of management, all adjustments consisting of normal recurring adjustments considered necessary for
the fair presentation of results for the interim period have been included. The results of
operations for the three months ended December 27, 2008 are not necessarily indicative of the
results expected for the full year. The accompanying unaudited consolidated condensed financial
statements should be read in conjunction with the financial statements and notes thereto included
in our Form 10-K for the fiscal year ended September 27, 2008. All references to years in these
financial statements are to fiscal years.
Note 2 Acquisitions and Equity Investment
On June 4, 2008, we acquired a 40% ownership in LTi REEnergy GmbH for cash of $28,288. LTi REEnergy
specializes in the design and manufacture of servo controllers as well as complete drive systems
for electric rotor blade controls for wind turbines. Sales for the twelve months preceding the
transaction were approximately $85,000. We are accounting for this investment using the equity
method of accounting with our net investment reflected in other assets on the balance sheet. We
expect to acquire the remaining 60% of the company in June 2009 subject to conventional conditions
of closing. Our 40% share of the net earnings of LTi REEnergy for the three months ended December
27, 2008 was $1,836 and is included in the operating results of our Industrial Systems segment.
All of our acquisitions are accounted for under the purchase method and, accordingly, the operating
results for the acquired companies are included in the consolidated statements of earnings from the
respective dates of acquisition.
On October 8, 2008, we acquired Berkeley Process Control, Inc. The purchase price, net of cash
acquired was $14,023, which was financed with credit facility borrowings. Berkeley manufactures
motion control software and hardware that automates the precise handling of semiconductor wafers
and enhances the speed, quality and safety of welding in the oil and gas market and in nuclear fuel
canisters. Sales for the twelve months preceding the acquisition were approximately $6,300. This
acquisition is included in our Industrial Systems segment.
On May 2, 2008, we acquired CSA Engineering, Inc. The purchase price, net of cash acquired, was
$15,277, which was financed with credit facility borrowings and a $2,000 unsecured note to the
sellers due June 30, 2009. CSA designs and supplies systems for vibration suppression, precision
motion control and dynamic testing of structures for the aerospace and defense markets. CSAs
specialized applications include satellite payload isolation systems, ground based test systems for
space and missile hardware, tuned mass dampers for vibration control and a jitter reduction control
system for the Airborne Laser optical bench. Sales for the 2007 calendar year were approximately
$14,000. This acquisition is included as part of our Space and Defense Controls segment.
On November 20, 2007, we acquired PRIZM Advanced Communication Electronics Inc. The purchase price,
net of cash acquired, was $12,000, which was financed with credit facility borrowings and issuance
of $3,000 of unsecured notes to the sellers due on March 31, 2009. PRIZM specializes in the design
of fiber optic and wireless video and data multiplexers used in commercial and military subsea
markets for oil and gas exploration, terrestrial robots and remote sensing applications. Sales for
the twelve months preceding the acquisition were approximately $5,000. This acquisition is included
in our Components segment.
Our purchase price allocations are complete with the exception of Berkeleys purchase price
allocation, which is based on preliminary estimates of fair values of assets acquired and
liabilities assumed.
Note 3 Inventories
|
|
|
|
|
|
|
|
|
|
|
|
December 27, |
|
|
September 27, |
|
|
|
2008 |
|
|
2008 |
|
|
Raw materials and purchased parts |
|
$ |
158,155 |
|
|
$ |
150,984 |
|
Work in progress |
|
|
210,456 |
|
|
|
203,331 |
|
Finished goods |
|
|
56,755 |
|
|
|
53,980 |
|
|
Total |
|
$ |
425,366 |
|
|
$ |
408,295 |
|
|
Note 4 - Goodwill and Intangible Assets
The changes in the carrying amount of goodwill for the three months ended December 27, 2008 are as
follows:
6
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of |
|
|
Current |
|
|
Foreign |
|
|
Balance as of |
|
|
|
September 27, |
|
|
Year |
|
|
Currency |
|
|
December 27, |
|
|
|
2008 |
|
|
Acquisitions |
|
|
Translation |
|
|
2008 |
|
|
Aircraft Controls |
|
$ |
103,925 |
|
|
$ |
- |
|
|
$ |
(44 |
) |
|
$ |
103,881 |
|
Space and Defense Controls |
|
|
81,790 |
|
|
|
- |
|
|
|
- |
|
|
|
81,790 |
|
Industrial Systems |
|
|
102,338 |
|
|
|
4,150 |
|
|
|
(3,309 |
) |
|
|
103,179 |
|
Components |
|
|
160,717 |
|
|
|
- |
|
|
|
(4,377 |
) |
|
|
156,340 |
|
Medical Devices |
|
|
111,965 |
|
|
|
- |
|
|
|
- |
|
|
|
111,965 |
|
|
Total |
|
$ |
560,735 |
|
|
$ |
4,150 |
|
|
$ |
(7,730 |
) |
|
$ |
557,155 |
|
|
The components of acquired intangible assets are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 27, 2008 |
|
|
September 27, 2008 |
|
|
|
Gross |
|
|
|
|
|
|
Gross |
|
|
|
|
|
|
Carrying |
|
|
Accumulated |
|
|
Carrying |
|
|
Accumulated |
|
|
|
Amount |
|
|
Amortization |
|
|
Amount |
|
|
Amortization |
|
|
Customer-related |
|
$ |
67,793 |
|
|
$ |
(24,890 |
) |
|
$ |
67,246 |
|
|
$ |
(23,506 |
) |
Technology-related |
|
|
36,339 |
|
|
|
(11,781 |
) |
|
|
33,238 |
|
|
|
(10,650 |
) |
Marketing-related |
|
|
16,687 |
|
|
|
(8,459 |
) |
|
|
16,719 |
|
|
|
(8,543 |
) |
Artistic-related |
|
|
25 |
|
|
|
(18 |
) |
|
|
25 |
|
|
|
(17 |
) |
|
Acquired intangible assets |
|
$ |
120,844 |
|
|
$ |
(45,148 |
) |
|
$ |
117,228 |
|
|
$ |
(42,716 |
) |
|
All acquired intangible assets other than goodwill are being amortized. Customer-related intangible
assets primarily consist of customer relationships. Technology-related intangible assets primarily
consist of technology, patents, intellectual property and engineering drawings. Marketing-related
intangible assets primarily consist of trademarks, trade names and non-compete agreements.
The weighted-average amortization period is eight years for customer-related, technology-related
and marketing-related intangible assets and ten years for artistic-related intangible assets. In
total, these intangible assets have a weighted-average life of eight years. Amortization of
acquired intangible assets was $3,441 for the three months ended December 27, 2008 and $3,709 for
the three months ended December 29, 2007. Based on acquired intangible assets recorded at December
27, 2008, amortization is expected to be $13,387 in 2009, $12,974 in 2010, $12,512 in 2011, $11,844
in 2012 and $9,441 in 2013.
Note 5 - Product Warranties
In the ordinary course of business, we warrant our products against defects in design, materials
and workmanship typically over periods ranging from twelve to thirty-six months. We determine
warranty reserves needed by product line based on historical experience and current facts and
circumstances. Activity in the warranty accrual is summarized as follows:
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
December 27, |
|
|
December 29, |
|
|
|
2008 |
|
|
2007 |
|
|
Warranty accrual at beginning of period |
|
$ |
10,015 |
|
|
$ |
7,123 |
|
Additions from acquisitions |
|
|
83 |
|
|
|
- |
|
Warranties issued during current period |
|
|
2,616 |
|
|
|
1,772 |
|
Reductions for settling warranties |
|
|
(1,571 |
) |
|
|
(1,087 |
) |
Foreign currency translation |
|
|
(239 |
) |
|
|
91 |
|
|
Warranty accrual at end of period |
|
$ |
10,904 |
|
|
$ |
7,899 |
|
|
7
Note 6 - Derivative Financial Instruments
We principally use derivative financial instruments to manage interest rate risk associated with
long-term debt and foreign exchange risk related to foreign operations and foreign currency
transactions. We enter into derivative financial instruments with a number of major financial
institutions to minimize counterparty credit risk.
Interest rate swaps are used to adjust the proportion of total debt that is subject to variable and
fixed interest rates. The interest rate swaps are designated as hedges of the amount of future cash
flows related to interest payments on variable-rate debt that, in combination with the interest
payments on the debt, convert a portion of the variable-rate debt to fixed-rate debt. At December
27, 2008, we had interest rate swaps with notional amounts totaling $75,000. Based on the
applicable margin at December 27, 2008, the interest rate swaps effectively convert this amount of
variable-rate debt to fixed-rate debt at 5.4% through their maturities in 2010, at which time the
interest will revert back to variable rates based on LIBOR plus the applicable margin. At December
27, 2008 and September 27, 2008, the fair value of interest rate swaps was a net $1,894 liability
and a net $976 liability, respectively, most of which is included in other accrued liabilities.
We use foreign currency forward contracts to purchase foreign currencies to fix the exchange rates
on future payments. The foreign currency forwards are designated as hedges of the amount of future
cash flows related to the payments. At December 27, 2008, we had outstanding foreign currency
forwards with notional amounts of $11,181. These contracts mature at various times through the
fourth quarter of 2009 and mitigate exposure in movements between the U.S. dollar and the
Philippine peso. At December 27, 2008, the fair value of these foreign currency forwards was a $408
asset, which is included in other current assets.
These interest rate swaps and foreign currency forwards are recorded in the consolidated balance
sheet at fair value and the related gains or losses are deferred in shareholders equity as a
component of Accumulated Other Comprehensive Income (Loss) (AOCI). These deferred gains and losses
are amortized into expense during the periods in which the related payments affect earnings.
However, to the extent the interest rate swaps and foreign currency forwards are not perfectly
effective in offsetting the change in the value of the payments being hedged, the ineffective
portion of these contracts is recognized in earnings immediately. Ineffectiveness was not material
in the first three months of 2009 or 2008.
Activity in Accumulated Other Comprehensive Income (Loss) (AOCI) related to these derivatives
during the first three months of 2009 is summarized below:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pre-Tax |
|
|
Income |
|
|
After-Tax |
|
|
|
Amount |
|
|
Tax |
|
|
Amount |
|
|
Balance at September 27, 2008 |
|
$ |
(818 |
) |
|
$ |
309 |
|
|
$ |
(509 |
) |
Net decrease in fair value of derivatives |
|
|
(735 |
) |
|
|
278 |
|
|
|
(457 |
) |
Net reclassification from AOCI into earnings |
|
|
161 |
|
|
|
(61 |
) |
|
|
100 |
|
|
Accumulated loss at December 27, 2008 |
|
$ |
(1,392 |
) |
|
$ |
526 |
|
|
$ |
(866 |
) |
|
We also have foreign currency exposure on intercompany loans that are denominated in a foreign
currency and are adjusted to current values using period-end exchange rates. The resulting gains or
losses are recorded in the statement of earnings. To minimize foreign currency exposure, we have
foreign currency forwards with notional amounts of $44,958. The foreign currency forwards are
recorded in the balance sheet at fair value and resulting gains or losses are recorded in the
statements of earnings, generally offsetting the gains or losses from the adjustments on the
intercompany loans. At December 27, 2008, the fair value of the foreign currency forwards was a
$604 asset, which was included in other current assets. At September 27, 2008, the fair value of
the foreign currency forwards was a $390 liability, which was included in other accrued
liabilities.
8
Note 7 Fair Value
In September 2006, the Financial Accounting Standards Board (FASB) issued Statement of Financial
Accounting Standard (SFAS) No. 157, Fair Value Measurements. This statement establishes a
framework for measuring fair value in generally accepted accounting principles, clarifies the
definition of fair value within that framework and expands disclosures about the use of fair value
measurement. SFAS No. 157 emphasizes that fair value is a market-based measurement, as opposed to a
transaction-specific measurement. We adopted SFAS No. 157 at the beginning of 2009.
Fair value is defined by SFAS No. 157 as the price that would be received to sell an asset or paid
to transfer a liability in an orderly transaction between market participants at the measurement
date. Depending on the nature of the asset or liability, various techniques and assumptions can be
used to estimate fair value. SFAS No. 157 defines the following fair value hierarchy:
Level 1 Quoted prices in active markets for identical assets and liabilities.
Level 2 Observable inputs other than quoted prices in active markets for similar assets and
liabilities.
Level 3 Inputs for which significant valuation assumptions are unobservable in a market and
therefore value is based on the best available data, some of which is internally developed and
considers risk premiums that a market participant would require.
The following table presents the fair values and classification of our financial assets and
liabilities measured on a recurring basis as of December 27, 2008:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Classification |
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
|
Total |
|
|
Foreign currency forwards |
|
Other current assets |
|
$ |
- |
|
|
$ |
1,012 |
|
|
$ |
- |
|
|
$ |
1,012 |
|
Interest rate swaps |
|
Other accrued liabilities |
|
|
- |
|
|
|
(1,871 |
) |
|
|
- |
|
|
|
(1,871 |
) |
Interest rate swaps |
|
Other long-term liabilities |
|
|
- |
|
|
|
(23 |
) |
|
|
- |
|
|
|
(23 |
) |
|
Net fair value |
|
|
|
$ |
- |
|
|
$ |
(882 |
) |
|
$ |
- |
|
|
$ |
(882 |
) |
|
We also adopted the provisions of SFAS No. 159, The Fair Value Option for Financial Assets and
Liabilities at the beginning of 2009. This statement permits entities to choose to measure many
financial instruments and certain other items at fair value. The objective is to improve financial
reporting by providing entities with the opportunity to mitigate volatility in reported earnings
caused by measuring related assets and liabilities differently without having to apply complex
hedge accounting provisions. We did not elect the fair value measurement option for any items that
are not already required to be measured at fair value.
Note 8 - Employee Benefit Plans
At the beginning of 2009, we implemented the measurement date provision of SFAS No. 158, Employers
Accounting for Defined Benefit Pension and Other Post-Retirement Plans, an amendment of FASB
Statements No. 87, 88, 106 and 132(R). The implementation of this statement reduced retained
earnings by $991 net of deferred taxes of $529, reduced other assets by $430, increased long-term
pension and retirement obligations by $867 and increased accumulated other comprehensive income by
$142, net of deferred taxes of $81.
Net periodic benefit costs for U.S. pension plans consist of:
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
December 27, |
|
|
December 29, |
|
|
|
2008 |
|
|
2007 |
|
|
Service cost |
|
$ |
3,494 |
|
|
$ |
4,115 |
|
Interest cost |
|
|
6,382 |
|
|
|
5,859 |
|
Expected return on plan assets |
|
|
(7,981 |
) |
|
|
(7,453 |
) |
Amortization of prior service cost |
|
|
74 |
|
|
|
265 |
|
Amortization of actuarial loss |
|
|
211 |
|
|
|
690 |
|
|
Pension expense for defined benefit plans |
|
|
2,180 |
|
|
|
3,476 |
|
Pension expense for defined contribution plans |
|
|
1,354 |
|
|
|
359 |
|
|
Total pension expense for U.S. plans |
|
$ |
3,534 |
|
|
$ |
3,835 |
|
|
9
Effective January 1, 2008, our U.S. defined benefit pension plan was amended to freeze enrollment
of new entrants. All new employees hired on or after January 1, 2008 are not eligible to
participate in the pension plan and, instead, we make contributions for those employees to an
employee-directed investment fund in the Moog Inc. Retirement Savings Plan (RSP). The Companys
contributions are based on a percentage of the employees eligible compensation and age. These
contributions are in addition to the employer match on voluntary employee contributions. We gave
all current employees participating in the pension plan as of January 1, 2008 the option to either
remain in the pension plan and continue to accrue benefits or to elect to stop accruing future
benefits in the pension plan as of April 1, 2008 and instead receive the new Company contribution
in the RSP. The employee elections became effective April 1, 2008. As a result of the employee
elections, there was an 18% reduction in expected future service to be considered in calculating
future benefits under the pension plan.
Net periodic benefit costs for non-U.S. pension plans consist of:
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
December 27, |
|
|
December 29, |
|
|
|
2008 |
|
|
2007 |
|
|
Service cost |
|
$ |
885 |
|
|
$ |
969 |
|
Interest cost |
|
|
1,425 |
|
|
|
1,434 |
|
Expected return on plan assets |
|
|
(871 |
) |
|
|
(915 |
) |
Amortization of prior service credit |
|
|
(12 |
) |
|
|
(9 |
) |
Amortization of actuarial loss |
|
|
118 |
|
|
|
84 |
|
|
Pension expense for defined benefit plans |
|
|
1,545 |
|
|
|
1,563 |
|
Pension expense for defined contribution plans |
|
|
412 |
|
|
|
441 |
|
|
Total pension expense for non-U.S. plans |
|
$ |
1,957 |
|
|
$ |
2,004 |
|
|
During the three months ended December 27, 2008, we made contributions to our defined benefit
pension plans of $6,000 to the U.S. plans and $1,573 to the non-U.S. plans. We anticipate
contributing an additional $18,000 to the U.S. plans and $4,800 to the non-U.S. plans for a total
of approximately $30,400 in 2009.
Net periodic benefit costs for the post-retirement health care benefit plan consist of:
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
December 27, |
|
|
December 29, |
|
|
|
2008 |
|
|
2007 |
|
|
Service cost |
|
$ |
104 |
|
|
$ |
107 |
|
Interest cost |
|
|
341 |
|
|
|
312 |
|
Amortization of transition obligation |
|
|
99 |
|
|
|
98 |
|
Amortization of prior service cost |
|
|
67 |
|
|
|
72 |
|
Amortization of actuarial loss |
|
|
96 |
|
|
|
112 |
|
|
Net periodic post-retirement benefit cost |
|
$ |
707 |
|
|
$ |
701 |
|
|
Note 9 Income Taxes
The effective tax rate for the first quarter of 2009 is lower than would be expected by applying
statutory tax rates on earnings before income taxes. The lower rate is a result of two factors that
occurred in the first quarter of 2009. We decided to repatriate approximately $31,000 of cash back
to the U.S. from our Japanese subsidiary. The average tax rate that we have paid in Japan has
exceeded our U.S. rate and, therefore, our repatriation decision results in a $4,850 foreign tax
credit, which reduces our U.S. tax provision. In addition, we recorded a $1,500 benefit in the
quarter related to our 2008 tax year as a result of the reinstatement of the U.S. research and
development tax credit under the recently enacted TARP legislation. Our effective tax rate for 2009
is expected to be 26,6%, reflecting these events..
10
Note 10 - Shareholders Equity
The changes in shareholders equity for the three months ended December 27, 2008 are summarized as
follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of Shares |
|
|
|
|
|
|
|
Class A |
|
|
Class B |
|
|
|
|
|
|
|
Common |
|
|
Common |
|
|
|
Amount |
|
|
Stock |
|
|
Stock |
|
|
COMMON STOCK |
|
|
|
|
|
|
|
|
|
|
|
|
Beginning and end of period |
$ |
|
48,605 |
|
|
|
40,793,523 |
|
|
|
7,811,190 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ADDITIONAL PAID-IN CAPITAL |
|
|
|
|
|
|
|
|
|
|
|
|
Beginning of period |
|
|
311,159 |
|
|
|
|
|
|
|
|
|
Equity-based compensation expense |
|
|
2,589 |
|
|
|
|
|
|
|
|
|
Issuance of Treasury shares at more than cost |
|
|
150 |
|
|
|
|
|
|
|
|
|
Income tax effect of equity-based compensation |
|
|
45 |
|
|
|
|
|
|
|
|
|
Adjustment to market - SECT |
|
|
(5,013 |
) |
|
|
|
|
|
|
|
|
|
|
|
End of period |
|
|
308,930 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
RETAINED EARNINGS |
|
|
|
|
|
|
|
|
|
|
|
|
Beginning of period |
|
|
688,585 |
|
|
|
|
|
|
|
|
|
Net earnings |
|
|
30,270 |
|
|
|
|
|
|
|
|
|
Adjustment for adoption of measurement provision of SFAS No. 158 |
|
|
(991 |
) |
|
|
|
|
|
|
|
|
|
|
|
End of period |
|
|
717,864 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TREASURY STOCK |
|
|
|
|
|
|
|
|
|
|
|
|
Beginning of period |
|
|
(40,607 |
) |
|
|
(2,107,949 |
) |
|
|
(3,305,971 |
) |
Issuance of treasury shares |
|
|
243 |
|
|
|
45,563 |
|
|
|
- |
|
Purchase of treasury shares |
|
|
(6,886 |
) |
|
|
(224,688 |
) |
|
|
- |
|
|
|
|
End of period |
|
|
(47,250 |
) |
|
|
(2,287,074 |
) |
|
|
(3,305,971 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
STOCK EMPLOYEE COMPENSATION TRUST (SECT) |
|
|
|
|
|
|
|
|
|
|
|
|
Beginning of period |
|
|
(22,179 |
) |
|
|
- |
|
|
|
(507,420 |
) |
Issuance of shares |
|
|
1,162 |
|
|
|
- |
|
|
|
34,831 |
|
Purchases of shares |
|
|
(261 |
) |
|
|
- |
|
|
|
(5,800 |
) |
Adjustment to market - SECT |
|
|
5,013 |
|
|
|
- |
|
|
|
- |
|
|
|
|
End of period |
|
|
(16,265 |
) |
|
|
- |
|
|
|
(478,389 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) |
|
|
|
|
|
|
|
|
|
|
|
|
Beginning of period |
|
|
8,847 |
|
|
|
|
|
|
|
|
|
Foreign currency translation adjustment |
|
|
(20,570 |
) |
|
|
|
|
|
|
|
|
Retirement liability adjustment |
|
|
1,201 |
|
|
|
|
|
|
|
|
|
Adjustment for adoption of measurement provision of SFAS No. 158 |
|
|
142 |
|
|
|
|
|
|
|
|
|
Increase in accumulated loss on derivatives |
|
|
(357 |
) |
|
|
|
|
|
|
|
|
|
|
|
End of period |
|
|
(10,737 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TOTAL SHAREHOLDERS EQUITY |
$ |
|
1,001,147 |
|
|
|
38,506,449 |
|
|
|
4,026,830 |
|
|
11
Note 11 - Stock Employee Compensation Trust
The Stock Employee Compensation Trust (SECT) assists in administering and provides funding for
equity-based compensation plans and benefit programs, including the Moog Inc. Retirement Savings
Plan. The shares in the SECT are not considered outstanding for purposes of calculating earnings
per share. However, in accordance with the trust agreement governing the SECT, the SECT trustee
votes all shares held by the SECT on all matters submitted to shareholders.
Note 12 - Earnings per Share
Basic and diluted weighted-average shares outstanding are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
December 27, |
|
|
December 29, |
|
|
|
2008 |
|
|
2007 |
|
|
Weighted-average shares outstanding - Basic |
|
|
42,607,289 |
|
|
|
42,485,328 |
|
Dilutive effect of equity-based awards |
|
|
378,799 |
|
|
|
773,332 |
|
|
Weighted-average shares outstanding - Diluted |
|
|
42,986,088 |
|
|
|
43,258,660 |
|
|
Note 13 - Comprehensive Income
The components of comprehensive income (loss), net of tax, are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
December 27, |
|
|
December 29, |
|
|
|
2008 |
|
|
2007 |
|
|
Net earnings |
|
$ |
30,270 |
|
|
$ |
27,675 |
|
Other comprehensive income (loss): |
|
|
|
|
|
|
|
|
Foreign currency translation adjustment |
|
|
(20,570 |
) |
|
|
5,967 |
|
Retirement liability adjustment, net of tax of $237
and $0, respectively |
|
|
1,201 |
|
|
|
- |
|
Increase in accumulated loss on derivatives |
|
|
(357 |
) |
|
|
(419 |
) |
|
Comprehensive income |
|
$ |
10,544 |
|
|
$ |
33,223 |
|
|
The components of accumulated other comprehensive income (loss), net of tax, are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
December 27, |
|
|
September 27, |
|
|
|
2008 |
|
|
2008 |
|
|
Cumulative foreign currency translation adjustment |
|
$ |
24,225 |
|
|
$ |
44,795 |
|
Accumulated retirement liability adjustments |
|
|
(34,096 |
) |
|
|
(35,439 |
) |
Accumulated loss on derivatives |
|
|
(866 |
) |
|
|
(509 |
) |
|
Accumulated other comprehensive (loss) income |
|
$ |
(10,737 |
) |
|
$ |
8,847 |
|
|
12
Note 14 - Segment Information
Below are sales and operating profit by segment for the three months ended December 27, 2008 and
December 29, 2007 and a reconciliation of segment operating profit to earnings before income taxes.
Operating profit is net sales less cost of sales and other operating expenses, excluding interest
expense, equity-based compensation expense and other corporate expenses. Cost of sales and other
operating expenses are directly identifiable to the respective segment or allocated on the basis of
sales, number of employees or profit.
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
December 27, |
|
|
December 29, |
|
|
|
2008 |
|
|
2007 |
|
|
Net sales: |
|
|
|
|
|
|
|
|
Aircraft Controls |
|
$ |
163,149 |
|
|
$ |
159,581 |
|
Space and Defense Controls |
|
|
71,382 |
|
|
|
57,347 |
|
Industrial Systems |
|
|
110,035 |
|
|
|
122,733 |
|
Components |
|
|
81,504 |
|
|
|
79,587 |
|
Medical Devices |
|
|
20,018 |
|
|
|
27,159 |
|
|
Net sales |
|
$ |
446,088 |
|
|
$ |
446,407 |
|
|
Operating profit and margins: |
|
|
|
|
|
|
|
|
Aircraft Controls |
|
$ |
13,500 |
|
|
$ |
15,088 |
|
|
|
|
8.3 |
% |
|
|
9.5 |
% |
|
|
|
|
|
|
|
|
|
Space and Defense Controls |
|
|
13,580 |
|
|
|
6,700 |
|
|
|
|
19.0 |
% |
|
|
11.7 |
% |
|
|
|
|
|
|
|
|
|
Industrial Systems |
|
|
11,499 |
|
|
|
17,893 |
|
|
|
|
10.5 |
% |
|
|
14.6 |
% |
|
|
|
|
|
|
|
|
|
Components |
|
|
15,001 |
|
|
|
14,836 |
|
|
|
|
18.4 |
% |
|
|
18.6 |
% |
Medical Devices |
|
|
(2,224 |
) |
|
|
3,587 |
|
|
|
|
(11.1 |
%) |
|
|
13.2 |
% |
|
Total operating profit |
|
|
51,356 |
|
|
|
58,104 |
|
|
|
|
11.5 |
% |
|
|
13.0 |
% |
|
|
|
|
|
|
|
|
|
Deductions from operating profit: |
|
|
|
|
|
|
|
|
Interest expense |
|
|
9,601 |
|
|
|
9,712 |
|
Equity-based compensation expense |
|
|
2,589 |
|
|
|
1,628 |
|
Corporate expenses and other |
|
|
2,793 |
|
|
|
4,334 |
|
|
Earnings before income taxes |
|
$ |
36,373 |
|
|
$ |
42,430 |
|
|
13
Note 15 - Recent Accounting Pronouncements
In December 2007, the FASB issued SFAS No. 141(R), Business Combinations. This statement replaces
SFAS No. 141. The objective of SFAS No. 141(R) is to improve the relevance, representational
faithfulness and comparability of the information that a reporting entity provides in its financial
reports about a business combination and its effects. It establishes principles and requirements
for the acquirer to recognize and measure the identifiable assets acquired, the liabilities
assumed, any noncontrolling interest in the acquiree, the goodwill acquired or a gain from a
bargain purchase. It also provides disclosure requirements to enable users of the financial
statements to evaluate the nature and financial effects of the business combination. SFAS No.
141(R) applies prospectively to business combinations for which the acquisition date is on or after
the beginning of the first annual reporting period beginning on or after December 15, 2008. This
statement will be effective for us at the beginning of 2010. Early adoption of this statement is
prohibited. We do not expect that the adoption of this standard will have a material impact on our
consolidated financial statements.
In December 2007, the FASB issued SFAS No. 160, Noncontrolling Interests in Consolidated Financial
Statements - an amendment of ARB No. 51. The objective of SFAS No. 160 is to improve the
relevance, comparability and transparency of the financial information that a reporting entity
provides in its consolidated financial statements by establishing additional accounting and
reporting standards. SFAS No. 160 is effective for fiscal years beginning on or after December 15,
2008. This statement will be effective for us at the beginning of 2010. Early adoption of this
statement is prohibited. We do not expect that the adoption of this standard will have a material
impact on our consolidated financial statements.
In March 2008, the FASB issued SFAS No. 161, Disclosures about Derivative Instruments and Hedging
Activities - an amendment of FASB Statement No. 133. The objective of SFAS No. 161 is to amend and
expand the disclosure requirements with the intent to provides users of financial statements with
an enhanced understanding of: (a) how and why an entity uses derivative instruments, (b) how
derivative instruments and related hedged items are accounted for under SFAS No. 133 and its
related interpretations and (c) how derivative instruments and related hedged items affect an
entitys financial position, financial performance and cash flows. SFAS No. 161 is effective for
fiscal years and interim periods beginning after November 15, 2008. This statement will be
effective beginning with our second quarter of 2009. We do not expect that the adoption of this
standard will have a material impact on our consolidated financial statements.
Note 16 Subsequent Events
On December 30, 2008, we acquired Aitecs Medical UAB, a Lithuanian-based manufacturer of
syringe-style infusion therapy pumps, for approximately $21,000 in cash, which was financed with
credit facility borrowings. Aitecs has a product portfolio that includes pumps for general hospital
use, operating rooms and patient controlled analgesia. Sales for the twelve months preceding the
acquisition were approximately $8,000. This acquisition will be included in our Medical Devices
segment.
On January 23, 2009, we acquired Ethox International for $15,200 in cash, which was financed with
credit facility borrowings. Ethox produces proprietary medical devices and is engaged in contract
manufacturing of disposables for medical device companies. Ethox also provides microbiology,
toxicology and sterilization services. Sales for the 2008 calendar year were approximately
$27,000. This acquisition will be included in our Medical Devices segment.
On January 30, 2009, we acquired 70% of the stock of Insensys Ltd. for approximately $16,000 in
cash. As part of the transaction, we have an option to purchase the remaining 30% within one year.
Insensys is a supplier of pitch control and rotor blade monitoring systems for wind turbines.
Sales for the 2008 calendar year were approximately $8,000. This acquisition will be included in
our Industrial Systems segment.
14
Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations.
The following should be read in conjunction with Managements Discussion and Analysis of Financial
Condition and Results of Operations contained in the Companys Form 10-K for the fiscal year ended
September 27, 2008. All references to years in this Managements Discussion and Analysis of
Financial Condition and Results of Operations are to fiscal years.
OVERVIEW
We are a worldwide designer, manufacturer and integrator of high performance precision motion and
fluid controls and control systems for a broad range of applications in aerospace and defense,
industrial and medical markets. Our aerospace and defense products and systems include military and
commercial aircraft flight controls, satellite positioning controls, controls for steering tactical
and strategic missiles, thrust vector controls for space launch vehicles, controls for gun aiming,
stabilization and automatic ammunition loading for armored combat vehicles, and homeland security
products. Our industrial products are used in a wide range of applications, including injection
molding machines, pilot training simulators, power generation, material and automotive testing,
metal forming, heavy industry and oil exploration. Our medical products include infusion therapy
pumps, enteral clinical nutrition pumps, slip rings used on CT scanners and motors used in sleep
apnea devices. We operate under five segments, Aircraft Controls, Space and Defense Controls,
Industrial Systems, Components and Medical Devices. Our principal manufacturing facilities are
located in the United States, including facilities in New York, California, Utah, Virginia, North
Carolina, Pennsylvania, Ohio and Illinois, and in Germany, England, Italy, Japan, the Philippines,
Ireland and India.
We have long-term contracts with some of our customers. These contracts are predominantly within
Aircraft Controls and Space and Defense Controls and represent approximately one-third of our
sales. We recognize revenue on these contracts using the percentage of completion, cost-to-cost
method of accounting as work progresses toward completion. The remainder of our sales are
recognized when the risks and rewards of ownership and title to the product are transferred to the
customer, principally as units are delivered or as service obligations are satisfied. This method
of revenue recognition is predominantly used within the Industrial Systems, Components and Medical
Devices segments, as well as with aftermarket activity.
We concentrate on providing our customers with products designed and manufactured to the highest
quality standards. In achieving a leadership position in the high performance, precision controls
market, we have capitalized on our strengths, which include:
|
|
|
superior technical competence and customer intimacy, |
|
|
|
|
customer diversity and broad product portfolio, |
|
|
|
|
well-established international presence serving customers worldwide, |
|
|
|
|
proven ability to successfully integrate acquisitions, and |
|
|
|
|
conservative capital structure and solid financial performance. |
We intend to increase our revenue base and improve our profitability and cash flows from operations
by building on our market leadership positions in the principal markets that we serve and by
extending our participation on the platforms we supply by providing more systems solutions. We also
expect to maintain a balanced, diversified portfolio in terms of markets served, product
applications, customer base and geographic presence. Our strategy to achieve our objectives
includes:
|
|
|
maintaining our technological excellence by building upon our systems integration
capabilities while solving our customers most demanding technical problems, |
|
|
|
|
taking advantage of our global capabilities, |
|
|
|
|
growing our profitable aftermarket business, |
|
|
|
|
capitalizing on strategic acquisitions and opportunities, |
|
|
|
|
entering and developing new markets, and |
|
|
|
|
striving for continuing cost improvements. |
Challenges facing us include adjusting to global economic conditions, improving shareholder value
through increased profitability while experiencing pricing pressures from customers, strong
competition and increases in costs such as health care benefits. We address these challenges by
focusing on strategic revenue growth and by continuing to improve operating efficiencies through
various process and manufacturing initiatives and using low cost manufacturing facilities without
compromising quality.
15
Acquisitions and Equity Investment
On June 4, 2008, we acquired a 40% ownership in LTi REEnergy GmbH for cash of $28 million. LTi
REEnergy specializes in the design and manufacture of servo controllers as well as complete drive
systems for electric rotor blade controls for wind turbines. Sales for the twelve months preceding
the transaction were approximately $85 million. We are accounting for this investment using the
equity method of accounting with our net investment reflected in other assets on the balance sheet.
We expect to acquire the remaining 60% of the company in June 2009 subject to conventional
conditions of closing. Our 40% share of the net earnings of LTi REEnergy for the three months ended
December 27, 2008 was $2 million and is included in the operating results of our Industrial Systems
segment.
All of our acquisitions are accounted for under the purchase method and, accordingly, the operating
results for the acquired companies are included in the consolidated statements of earnings from the
respective dates of acquisition.
On October 8, 2008, we acquired Berkeley Process Control, Inc. The purchase price, net of cash
acquired was $14 million, which was financed with credit facility borrowings. Berkeley manufactures
motion control software and hardware that automates the precise handling of semiconductor wafers
and enhances the speed, quality and safety of welding in the oil and gas market and in nuclear fuel
canisters. Sales for the twelve months preceding the acquisition were approximately $6 million.
This acquisition is included in our Industrial Systems segment.
On May 2, 2008, we acquired CSA Engineering, Inc. The purchase price, net of cash acquired, was
$15 million, which was financed with credit facility borrowings, and a $2 million unsecured note to
the sellers due June 30, 2009. CSA designs and supplies systems for vibration suppression,
precision motion control and dynamic testing of structures for the aerospace and defense markets.
CSAs specialized applications include satellite payload isolation systems, ground based test
systems for space and missile hardware, tuned mass dampers for vibration control and a jitter
reduction control system for the Airborne Laser optical bench. Sales for the 2007 calendar year
were approximately $14 million. This acquisition is included as part of our Space and Defense
Controls segment.
On November 20, 2007, we acquired PRIZM Advanced Communication Electronics Inc. The purchase price,
net of cash acquired, was $12 million, which was financed with credit facility borrowings and
issuance of $3 million of unsecured notes to the sellers due on March 31, 2009. PRIZM specializes
in the design of fiber optic and wireless video and data multiplexers used in commercial and
military subsea markets, for oil and gas exploration, terrestrial robots and remote sensing
applications. Annual sales for the twelve months preceding the acquisition were approximately $5
million. This acquisition is included in our Components segment.
Our purchase price allocations are complete with the exception of Berkeleys purchase price
allocation, which is based on preliminary estimates of fair values of assets acquired and
liabilities assumed.
On December 30, 2008, we acquired Aitecs Medical UAB, a Lithuanian-based manufacturer of
syringe-style infusion therapy pumps, for approximately $21 million in cash, which was financed
with credit facility borrowings. Aitecs has a product portfolio that includes pumps for general
hospital use, operating rooms and patient controlled analgesia. Sales for the twelve months
preceding the acquisition were approximately $8 million. This acquisition will be included in our
Medical Devices segment.
On January 23, 2009, we acquired Ethox International for $15 million in cash, which was financed
with credit facility borrowings. Ethox produces proprietary medical devices and is engaged in
contract manufacturing of disposables for medical device companies. Ethox also provides
microbiology, toxicology and sterilization services. Sales for the 2008 calendar year were
approximately $27 million. This acquisition will be included in our Medical Devices segment.
On January 30, 2009, we acquired 70% of the stock of Insensys Ltd. for approximately $16 million in
cash. As part of the transaction, we have an option to purchase the remaining 30% within one year.
Insensys is a supplier of pitch control and rotor blade monitoring systems for wind turbines.
Sales for the 2008 calendar year were approximately $8 million. This acquisition will be included
in our Industrial Systems segment.
16
CRITICAL ACCOUNTING POLICIES
There have been no changes in critical accounting policies in the current year from those disclosed
in our 2008 Form 10-K.
RECENT ACCOUNTING PRONOUNCEMENTS
In December 2007, the FASB issued SFAS No. 141(R), Business Combinations. This statement replaces
SFAS No. 141. The objective of SFAS No. 141(R) is to improve the relevance, representational
faithfulness and comparability of the information that a reporting entity provides in its financial
reports about a business combination and its effects. It establishes principles and requirements
for the acquirer to recognize and measure the identifiable assets acquired, the liabilities
assumed, any noncontrolling interest in the acquiree, the goodwill acquired or a gain from a
bargain purchase. It also provides disclosure requirements to enable users of the financial
statements to evaluate the nature and financial effects of the business combination. SFAS No.
141(R) applies prospectively to business combinations for which the acquisition date is on or after
the beginning of the first annual reporting period beginning on or after December 15, 2008. This
statement will be effective for us at the beginning of 2010. Early adoption of this statement is
prohibited. We do not expect that the adoption of this standard will have a material impact on our
consolidated financial statements.
In December 2007, the FASB issued SFAS No. 160, Noncontrolling Interests in Consolidated Financial
Statements - an amendment of ARB No. 51. The objective of SFAS No. 160 is to improve the
relevance, comparability and transparency of the financial information that a reporting entity
provides in its consolidated financial statements by establishing additional accounting and
reporting standards. SFAS No. 160 is effective for fiscal years beginning on or after December 15,
2008. This statement will be effective for us at the beginning of 2010. Early adoption of this
statement is prohibited. We do not expect that the adoption of this standard will have a material
impact on our consolidated financial statements.
In March 2008, the FASB issued SFAS No. 161, Disclosures about Derivative Instruments and Hedging
Activities - an amendment of FASB Statement No. 133. The objective of SFAS No. 161 is to amend and
expand the disclosure requirements with the intent to provides users of financial statements with
an enhanced understanding of: (a) how and why an entity uses derivative instruments, (b) how
derivative instruments and related hedged items are accounted for under SFAS No. 133 and its
related interpretations and (c) how derivative instruments and related hedged items affect an
entitys financial position, financial performance and cash flows. SFAS No. 161 is effective for
fiscal years and interim periods beginning after November 15, 2008. This statement will be
effective beginning with our second quarter of 2009. We do not expect that the adoption of this
standard will have a material impact on our consolidated financial statements.
17
CONSOLIDATED RESULTS OF OPERATIONS AND OUTLOOK
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
December 27, |
|
|
December 29, |
|
(dollars in millions) |
|
2008 |
|
|
2007 |
|
|
Net sales |
|
$ |
446.1 |
|
|
$ |
446.4 |
|
Gross margin |
|
|
30.9 |
% |
|
|
33.1 |
% |
Research and development expenses |
|
$ |
25.1 |
|
|
$ |
24.1 |
|
Selling, general and administrative expenses as
a percentage of sales |
|
|
15.5 |
% |
|
|
16.0 |
% |
Interest expense |
|
$ |
9.6 |
|
|
$ |
9.7 |
|
Effective tax rate |
|
|
16.8 |
% |
|
|
34.8 |
% |
Net earnings |
|
$ |
30.3 |
|
|
$ |
27.7 |
|
|
Net sales were relatively unchanged in the first quarter of 2009 compared to the first quarter of
2008. Approximately one-fourth of our 2009 sales were denominated in foreign currencies including
the euro, British pound and Japanese yen. During the first three months of 2009, these foreign
currencies weakened against the U.S. dollar and the translation of the results of our foreign
subsidiaries into U.S. dollars decreased sales by $12 million compared to the same period one year
ago.
Our gross margin was lower in the first quarter of 2009 compared to 2008. Our gross margin was
affected by additions to contract loss reserves, which were $7 million higher in the first quarter
of 2009 compared to the first quarter of 2008, primarily related to loss reserves in our Aircraft
Controls segment.
Research and development expenses increased $1 million in the first quarter of 2009 compared to the
same period of 2008. The higher level of research and development expenses was primarily a result
of development activities in our Medical Devices segment.
Selling, general and administrative expenses as a percentage of sales were lower in the first
quarter of 2009 compared to the same period last year. The decrease is primarily a result of
managements curtailment of discretionary expenses in conjunction with the global economic
slowdown. In addition, we had a sales volume shift in the first quarter of 2009 to segments that
have lower selling, general and administrative cost structures.
Interest expense was comparable in the first quarter of 2009 to the same period of 2008 as a result
of higher debt levels being offset by lower average interest rates.
The effective tax rate for the first quarter of 2009 was lower compared to the same period for
2008. This was a result of two items that occurred in the first quarter of 2009. We decided to
repatriate approximately $31 million of cash back to the U.S. from our Japanese subsidiary. The
average tax rate that we have paid in Japan has exceeded our U.S. rate and, therefore, our
repatriation decision results in a $5 million foreign tax credit, which reduces our U.S. tax
provision. In addition, we recorded a $1.5 million benefit in the quarter related to our 2008 tax
year as a result of the reinstatement of the U.S. research and development tax credit under the
recently enacted TARP legislation. Our effective tax rate for 2009 is expected to be 26.6%,
reflecting these events.
Net earnings and diluted earnings per share increased 9% in the first quarter of 2009.
2009 Outlook - We expect sales in 2009 to increase by 3% to approximately $1.96 billion with
increases in each of our segments with the exception of Industrial Systems, where we expect a
decline of $8 million. Sales are expected to increase $28 million in Space and Defense Controls,
$25 million in Medical Devices, $7 million in Aircraft Controls and $2 million in Components over
2008. We expect operating margins to be approximately 11.4% in 2009 compared to 12.0% in 2008. We
expect operating margins to increase in Space and Defense Controls and Aircraft Controls, maintain
their level in Components and decline in Medical Devices and Industrial Systems. We expect net
earnings to increase to $121 million and diluted earnings per share to increase by 2% to $2.80.
18
SEGMENT RESULTS OF OPERATIONS AND OUTLOOK
Operating profit, as presented below, is net sales less cost of sales and other operating expenses,
excluding interest expense, equity-based compensation expense and other corporate expenses. Cost of
sales and other operating expenses are directly identifiable to the respective segment or allocated
on the basis of sales, number of employees or profit. Operating profit is reconciled to earnings
before income taxes in Note 14 of the Notes to Consolidated Condensed Financial Statements included
in this report.
Aircraft Controls
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
December 27, |
|
|
December 29, |
|
(dollars in millions) |
|
2008 |
|
|
2007 |
|
|
Net sales - military aircraft |
|
$ |
105.6 |
|
|
$ |
90.8 |
|
Net sales - commercial aircraft |
|
|
57.5 |
|
|
|
68.8 |
|
|
|
|
$ |
163.1 |
|
|
$ |
159.6 |
|
Operating profit |
|
$ |
13.5 |
|
|
$ |
15.1 |
|
Operating margin |
|
|
8.3 |
% |
|
|
9.5 |
% |
Backlog |
|
$ |
374.9 |
|
|
$ |
322.1 |
|
|
Net sales in Aircraft Controls increased $4 million, or 2%, in the first quarter of 2009. Military
aircraft sales increased $15 million. Sales increased $8 million on the F-35 program as we started
work on the low-rate production contract, $3 million on the Indian Light Combat Aircraft as a
result of a new order for flight controls and $3 million on the V-22 Osprey production program.
Military aftermarket sales also increased $3 million in the quarter. Commercial aircraft sales
decreased $11 million from the first quarter of 2008, mainly due to $8 million in lower sales to
Boeing, partly as a result of their production strike and a $3 million decline in sales for
business jets.
Our operating margin was lower in the first quarter of 2009 compared to 2008 as we increased our
loss reserves in the first quarter of 2009. Excluding the effects of the additions to loss
reserves, our operating margins would have increased compared to 2008, primarily as a result of
sales mix changes.
The higher level of twelve-month backlog for Aircraft Controls at December 27, 2008 compared to
December 29, 2007 reflects strong military orders offset by a decline in commercial backlog.
2009
Outlook for Aircraft Controls - We expect sales in Aircraft Controls to increase slightly to
$680 million in 2009. Military aircraft sales are expected to increase 4% to $420 million mainly
due to increases in military aftermarket. Commercial aircraft sales are expected to decrease 4% to
$260 million, principally related to Boeing and commercial aftermarket, partially offset by an
increase in sales to Airbus. We expect our operating margin to be 9.3% in 2009, an improvement
from 8.2% in 2008, as research and development spending moderates and becomes a lower percentage of
sales.
19
Space and Defense Controls
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
December 27, |
|
|
December 29, |
|
(dollars in millions) |
|
2008 |
|
|
2007 |
|
|
Net sales |
|
$ |
71.4 |
|
|
$ |
57.3 |
|
|
|
|
|
|
|
|
|
|
Operating profit |
|
$ |
13.6 |
|
|
$ |
6.7 |
|
|
|
|
|
|
|
|
|
|
Operating margin |
|
|
19.0 |
% |
|
|
11.7 |
% |
|
|
|
|
|
|
|
|
|
Backlog |
|
$ |
153.8 |
|
|
$ |
166.4 |
|
|
Net sales in Space and Defense Controls increased $14 million, or 24%, in the first quarter of 2009
compared to 2008. Sales of defense controls increased $8 million as a result from a large order on
the Drivers Vision Enhancer (DVE) program. CSA Engineering, which we acquired in the third quarter
of 2008, also contributed $4 million of sales in vibration suppression and shock isolation systems.
Our operating margin for Space and Defense Controls increased significantly in the first quarter of
2009. The increase resulted primarily from the volume and profitability on the DVE program in the
first quarter of 2009 and first year purchase accounting adjustments in the first quarter of 2008.
The lower level of twelve-month backlog at December 27, 2008 compared to December 29, 2007 relates
to the decline in orders of defense controls, primarily the DVE program.
2009
Outlook for Space and Defense Controls We expect sales in Space and Defense Controls to
increase $28 million, or 11%, to $281 million in 2009. We expect nearly half of the increase to
come from CSA. We also expect sales increases in tactical missiles, naval applications, satellites
and launch vehicles. We expect our operating margin in 2009 to increase to 13.4% from 11.6% in
2008, primarily as a result of the strong performance in the first quarter.
Industrial Systems
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
December 27, |
|
|
December 29, |
|
(dollars in millions) |
|
2008 |
|
|
2007 |
|
|
Net sales |
|
$ |
110.0 |
|
|
$ |
122.7 |
|
|
|
|
|
|
|
|
|
|
Operating profit |
|
$ |
11.5 |
|
|
$ |
17.9 |
|
|
|
|
|
|
|
|
|
|
Operating margin |
|
|
10.5 |
% |
|
|
14.6 |
% |
|
|
|
|
|
|
|
|
|
Backlog |
|
$ |
149.2 |
|
|
$ |
169.7 |
|
|
Net sales in Industrial Systems decreased $13 million, or 10%, in the first quarter of 2009
compared to 2008. Weaker foreign currencies, in particular the euro, compared to the U.S. dollar
had a negative impact on sales, representing 40% of the sales decrease in the quarter. Sales were
down in all of our major markets except for motion simulation and power generation. Sales for
plastic making machinery decreased $7 million, which related to weaker demand in the auto industry
and packaging for consumer goods. Sales for controls in steel mills decreased $5 million in China
and Europe due to slowing global demand. Sales for controls for metal forming presses decreased by
$3 million due to the lack of demand in the auto industry, particularly in Japan. Offsetting those
sales declines were increases of $4 million in the motion simulator business and $3 million in
power generation related to continuing strong demand in Europe and Asia.
Our operating margin for Industrial Systems declined in the first quarter of 2009 over the
comparable 2008 period due to lower sales volume.
The lower level of twelve-month backlog for Industrial Systems at December 27, 2008 compared to
December 29, 2007 primarily relates to slowing demand in all of our major markets.
2009
Outlook for Industrial Systems We expect sales in Industrial Systems to decrease 2% to $524
million in 2009. We expect sales declines in most of our major markets as a result of slowing
global demand and weaker foreign currencies. The exceptions include test equipment, which is
expected to remain flat, and power generation, which will increase as we expect to complete the
acquisition of LTi REEnergy later in the year. We expect our operating margin to decrease to 10.4%
in 2009 from 13.8% in 2008 as a result of the decrease in sales volume.
20
Components
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
December 27, |
|
|
December 29, |
|
(dollars in millions) |
|
2008 |
|
|
2007 |
|
|
Net sales |
|
$ |
81.5 |
|
|
$ |
79.6 |
|
|
|
|
|
|
|
|
|
|
Operating profit |
|
$ |
15.0 |
|
|
$ |
14.8 |
|
|
|
|
|
|
|
|
|
|
Operating margin |
|
|
18.4 |
% |
|
|
18.6 |
% |
|
|
|
|
|
|
|
|
|
Backlog |
|
$ |
188.5 |
|
|
$ |
170.2 |
|
|
Net sales in Components increased $2 million, or 2%, in the first quarter of 2009 compared to 2008.
Sales increased in every market except industrial. Aircraft sales increased $2 million, primarily
on the Guardian program, a system designed to protect aircraft from shoulder-fired missiles. Sales
of space and defense controls increased $1 million for components supplied on the Abrams Tank and
the Stryker Mobile Gun System. Marine sales increased $1 million, mostly for equipment used on
undersea robots. Total medical sales were unchanged as sales to Respironics increased $1 million,
offset by decreases in sales of slip rings for CT scan customers. Industrial sales decreased $4
million, largely a result of reduced demand for industrial automation equipment.
Our operating margin was relatively unchanged in the first quarter of 2009 compared to 2008.
The higher level of twelve-month backlog at December 27, 2008 compared to December 29, 2007
primarily relates to increased orders for military aircraft, principally the Guardian program, and
defense controls programs.
2009
Outlook for Components - We expect sales in Components to remain relatively flat at $343
million in 2009. We expect sales increases in aircraft, which is primarily driven by the Guardian
program, and from the space and defense market. We expect sales within the marine market to remain
flat, while we experience decreases within the medical and industrial markets. We expect our
operating margin in 2009 to be 17.8% in 2009, reflecting the same strong performance we achieved in
2008.
Medical Devices
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
December 27, |
|
|
December 29, |
|
(dollars in millions) |
|
2008 |
|
|
2007 |
|
|
Net sales |
|
$ |
20.0 |
|
|
$ |
27.2 |
|
|
|
|
|
|
|
|
|
|
Operating profit (loss) |
|
$ |
(2.2 |
) |
|
$ |
3.6 |
|
|
|
|
|
|
|
|
|
|
Operating margin |
|
|
(11.1 |
%) |
|
|
13.2 |
% |
|
|
|
|
|
|
|
|
|
Backlog |
|
$ |
11.4 |
|
|
$ |
11.3 |
|
|
Net sales in Medical Devices decreased $7 million, or 26%, in the first quarter of 2009 compared to
2008. Sales for pumps decreased $6 million, resulting from reduced spending by hospitals and
outpatient clinics in the first quarter of 2009 and a large order in the first quarter of 2008.
Sales of sensors and hand pieces decreased $2 million, or 37%, in the quarter. Partially offsetting
those sales decreases was an increase in sales for administration sets of $1 million, or 20%, in
the quarter.
Our operating margin declined in the first quarter of 2009 relative to 2008 primarily as a result
of the lower sales volume, a $1 million reserve established for a voluntary software modification
for certain of our enteral feeding pumps and increased research and development spending.
Twelve-month backlog for Medical Devices is not as substantial relative to sales as in our other
segments, reflecting the shorter order-to-shipment cycle for this line of business.
2009
Outlook for Medical Devices We expect sales in Medical Devices to increase 24% to $129
million in 2009, solely as a result of two acquisitions we completed after the end of the first
quarter. The acquisitions of Aitecs and Ethox International are expected to add approximately $24
million in sales for the remainder of 2009. We expect our operating margin to decrease to 6.0% as a
result of the operating loss in the first quarter and the impact of first year purchase accounting
charges on the Aitecs and Ethox acquisitions.
21
FINANCIAL CONDITION AND LIQUIDITY
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
December 27, |
|
|
December 29, |
|
(dollars in millions) |
|
2008 |
|
|
2007 |
|
|
Net cash provided (used) by: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating activities |
|
$ |
32.5 |
|
|
$ |
(3.7 |
) |
|
|
|
|
|
|
|
|
|
Investing activities |
|
|
(34.5 |
) |
|
|
(35.5 |
) |
|
|
|
|
|
|
|
|
|
Financing activities |
|
|
36.1 |
|
|
|
36.8 |
|
|
Our available borrowing capacity and our cash flow from operations provide us with the financial
resources needed to run our operations, reinvest in our business and make strategic acquisitions.
Operating activities
Net cash provided by operating activities increased in the first quarter of 2009 compared to 2008.
This increase relates primarily to increased collections of receivables in 2009 and the greater
working capital requirements to support the 25% sales growth of our operations in the first quarter
2008. Partially offsetting this increase were larger uses of cash in the first quarter of 2009
compared to 2008 for various items such as higher pension contributions.
Investing activities
Net cash used by investing activities in the first three months of 2009 consisted of $20 million
for capital expenditures and $14 million for the acquisition of Berkeley Process Controls. Net cash
used by investing activities in the first quarter of 2008 consisted principally of $25 million of
capital expenditures and $9 million towards the acquisition of PRIZM.
Our capital expenditures in 2009 will approximate $95 million.
Financing activities
Net cash provided by financing activities in the first three months of 2009 reflects borrowings on
our U.S. credit facility for acquisitions, operations and $7 million used for our recently
announced share repurchase program. Net cash provided by financing activities in the first quarter
of 2008 reflects the use of our U.S. credit facility for increased working capital requirements to
fund our sales growth, capital expenditures and the acquisition of PRIZM.
Off Balance Sheet Arrangements
We do not have any material off balance sheet arrangements that have or are reasonably likely to
have a material future effect on our results of operations or financial condition.
Contractual Obligations and Commercial Commitments
Our contractual obligations and commercial commitments have not changed materially from the
disclosures in our 2008 Form 10-K.
22
CAPITAL STRUCTURE AND RESOURCES
We maintain bank credit facilities to fund our short and long-term capital requirements, including
for acquisitions. From time to time, we also sell equity and debt securities to fund acquisitions
or take advantage of favorable market conditions.
Our largest credit facility is our U.S. credit facility, which matures on March 14, 2013. It
consists of a $750 million revolver and had an outstanding balance of $290 million at December 27,
2008. Interest on outstanding credit facility borrowings is based on LIBOR plus the applicable
margin, which was 125 basis points at December 27, 2008. The credit facility is secured by
substantially all of our U.S. assets.
The U.S. credit facility contains various covenants. The covenant for minimum net worth, defined as
total shareholders equity adjusted to maintain the amounts of accumulated other comprehensive loss
at the level in existence as of September 30, 2006 is $600 million. The covenant for minimum
interest coverage ratio, defined as the ratio of EBITDA to interest expense for the most recent
four quarters, is 3.0. The covenant for the maximum leverage ratio, defined as the ratio of net
debt including letters of credit to EBITDA for the most recent four quarters, is 3.5. The covenant
for maximum capital expenditures is $100 million annually. EBITDA is defined in the loan agreement
as (i) the sum of net income, interest expense, income taxes, depreciation expense, amortization
expense, other non-cash items reducing consolidated net income and non-cash equity-based
compensation expenses minus (ii) other non-cash items increasing consolidated net income. We are in
compliance with all covenants.
We are required to obtain the consent of lenders of the U.S. credit facility before raising
significant additional debt financing. In recent years, we have demonstrated our ability to secure
consents to access debt markets. We have also been successful in accessing equity markets and have
shown strong, consistent financial performance. We believe that we will be able to obtain
additional debt or equity financing as needed.
At December 27, 2008, we had $478 million of unused borrowing capacity, including $448 million from
the U.S. credit facility after considering standby letters of credit.
Net debt to capitalization was 37% at December 27, 2008 and September 27, 2008.
We believe that our cash on hand, cash flows from operations and available borrowings under short
and long-term lines of credit will continue to be sufficient to meet our operating needs.
23
ECONOMIC CONDITIONS AND MARKET TRENDS
We operate within the aerospace and defense, industrial and medical markets. Our aerospace and
defense markets are affected by market conditions and program funding levels, while our industrial
markets are influenced by general capital investment trends. Our medical markets are influenced by
population demographics, medical advances and patient demand. A common factor throughout our
markets is the continuing demand for technologically advanced products.
Aerospace and Defense
Approximately 58% of our 2008 sales were generated in aerospace and defense markets. The military
aircraft market is dependent on military spending for development and production programs.
Production programs are typically long-term in nature, offering predictability as to capacity needs
and future revenues. We maintain positions on numerous high priority programs, including the F-35
Joint Strike Fighter, F/A-18E/F Super Hornet and V-22 Osprey. The large installed base of our
products leads to attractive aftermarket sales and service opportunities. Aftermarket revenues are
expected to continue to grow due to a number of scheduled military retrofit programs and increased
flight hours resulting from increased military commitments.
The commercial OEM market has historically exhibited cyclical swings and sensitivity to economic
conditions, while the aftermarket, which is driven by usage of the existing aircraft fleet, has
proven to be more stable. Higher aircraft utilization rates result in the need for increased
maintenance and spare parts and enhance aftermarket sales. Boeing and Airbus have increased
production over the last several years as air traffic volume has grown.
The military and government space market is primarily dependent on the authorized levels of funding
for satellite communications. Government spending on military satellites has risen in recent years
as the militarys need for improved intelligence gathering has increased. The commercial space
market is comprised of large satellite customers, traditionally telecommunications companies.
Trends for this market, as well as for commercial launch vehicles, follow the telecommunications
companies need for increased capacity and the satellite replacement lifecycle of 7-10 years. Our
position on NASAs Constellation Program for the exploration of the Moon and possibly Mars holds
the potential to be a long-run production program.
The tactical missile, missile defense and defense controls markets are dependent on many of the
same market conditions as military aircraft, including overall military spending and program
funding levels. Our homeland security product line is dependent on government funding at federal
and local levels, as well as private sector demand.
Industrial
Approximately 34% of our 2008 sales were generated in industrial markets. The industrial markets
we serve are influenced by several factors, including capital investment, product innovation,
economic growth, cost-reduction efforts and technology upgrades. We are experiencing challenges
from current global economic conditions. These challenges include reacting to slowing demand for
industrial automation equipment, steel and automotive manufacturing and delayed orders as customers
manage inventory levels. Despite the general slowdown in demand from the global recession, we
continue to see strong demand for our pitch control systems in the growing wind energy market.
Medical
Approximately 8% of our 2008 sales were generated in medical markets. The medical markets we serve
are influenced by hospital and outpatient clinic spending on equipment, population demographics,
medical advances, patient demands and the need for precision control components and systems.
Advances in medical technology and medical treatments have had the effect of extending the average
life span, in turn resulting in greater need for medical services. These same technology and
treatment advances also drive increased demand from the general population as a means to improve
quality of life. Greater access to medical insurance, whether through government funded health
care plans or private insurance, also increases the demand for medical services.
24
Foreign Currencies
We are affected by the movement of foreign currencies compared to the U.S. dollar, particularly in
Industrial Systems. About one-third of our 2008 sales were denominated in foreign currencies
including the euro, British pound and Japanese yen. During the first three months of 2009, these
foreign currencies weakened against the U.S. dollar and the translation of the results of our
foreign subsidiaries into U.S. dollars decreased sales by $12 million compared to the same period
one year ago. During 2008, these foreign currencies strengthened against the U.S. dollar and the
translation of the results of our foreign subsidiaries into U.S. dollars increased sales by $49
million compared to 2007.
Pension
The assumptions for our 2009 net periodic pension costs and funding requirements were determined as
of August 31, 2008. Therefore, our 2009 expense and funding requirements will not be impacted by
the recent decline in global equity markets. Changes in the fair market value of our pension assets
between August 31, 2008 and the end of 2009 will impact our expense over a five-year period
beginning in 2010.
25
Cautionary Statement
Information included or incorporated by reference in this report that does not consist of
historical facts, including statements accompanied by or containing words such as may, will,
should, believes, expects, expected, intends, plans, projects, estimates,
predicts, potential, outlook, forecast, anticipates, presume and assume, are
forward-looking statements. Such forward-looking statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. These statements are not
guarantees of future performance and are subject to several factors, risks and uncertainties, the
impact or occurrence of which could cause actual results to differ materially from the expected
results described in the forward-looking statements. These important factors, risks and
uncertainties include:
|
|
|
fluctuations in general business cycles for commercial aircraft, military aircraft,
space and defense products, industrial capital goods and medical devices, |
|
|
|
|
our dependence on government contracts that may not be fully funded or may be
terminated, |
|
|
|
|
our dependence on certain major customers, such as The Boeing Company and Lockheed
Martin, for a significant percentage of our sales, |
|
|
|
|
delays by our customers in the timing of introducing new products, which may affect our
earnings and cash flow, |
|
|
|
|
the possibility that the demand for our products may be reduced if we are unable to
adapt to technological change, |
|
|
|
|
intense competition which may require us to lower prices or offer more favorable terms
of sale, |
|
|
|
|
our indebtedness which could limit our operational and financial flexibility, |
|
|
|
|
the possibility that new product and research and development efforts may not be
successful, which could reduce our sales and profits, |
|
|
|
|
increased cash funding requirements for pension plans, which could occur in future years
based on assumptions used for our defined benefit pension plans, including returns on plan
assets and discount rates, |
|
|
|
|
a write-off of all or part of our goodwill, which could adversely affect our operating
results and net worth and cause us to violate covenants in our bank agreements, |
|
|
|
|
the potential for substantial fines and penalties or suspension or debarment from future
contracts in the event we do not comply with regulations relating to defense industry
contracting, |
|
|
|
|
the potential for cost overruns on development jobs and fixed price contracts and the
risk that actual results may differ from estimates used in contract accounting, |
|
|
|
|
the possibility that our subcontractors may fail to perform their contractual
obligations, which may adversely affect our contract performance and our ability to obtain
future business, |
|
|
|
|
our ability to successfully identify and consummate acquisitions, and integrate the
acquired businesses and the risks associated with acquisitions, including that the acquired
businesses do not perform in accordance with our expectations, and that we assume unknown
liabilities in connection with the acquired businesses for which we are not indemnified, |
|
|
|
|
our dependence on our management team and key personnel, |
|
|
|
|
the possibility of a catastrophic loss of one or more of our manufacturing facilities, |
|
|
|
|
the possibility that future terror attacks, war or other civil disturbances could
negatively impact our business, |
|
|
|
|
that our operations in foreign countries could expose us to political risks and adverse
changes in local, legal, tax and regulatory schemes, |
|
|
|
|
the possibility that government regulation could limit our ability to sell our products
outside the United States, |
|
|
|
|
product quality or patient safety issues with respect to our medical devices business
that could lead to product recalls, withdrawal from certain markets, delays in the
introduction of new products, sanctions, litigation, declining sales or actions of
regulatory bodies and government authorities, |
|
|
|
|
the impact of product liability claims related to our products used in applications
where failure can result in significant property damage, injury or death and in damage to
our reputation, |
|
|
|
|
changes in medical reimbursement rates of insurers to medical service providers, which
could affect sales of our medical products, |
|
|
|
|
the possibility that litigation may result unfavorably to us, |
|
|
|
|
our ability to adequately enforce our intellectual property rights and the possibility
that third parties will assert intellectual property rights that prevent or restrict our
ability to manufacture, sell, distribute or use our products or technology, |
|
|
|
|
foreign currency fluctuations in those countries in which we do business and other risks
associated with international operations, |
|
|
|
|
the cost of compliance with environmental laws, |
|
|
|
|
the risk of losses resulting from maintaining significant amounts of cash and cash
equivalents at financial institutions that are in excess of amounts insured by governments, |
|
|
|
|
the inability to utilize amounts available to us under our credit facilities given
uncertainties in the credit markets and |
|
|
|
|
our customers inability to pay us due to adverse economic conditions or their inability
to access available credit. |
|
|
The factors identified above are not exhaustive. New factors, risks and uncertainties may emerge
from time to time that may affect the forward-looking statements made herein. Given these
factors, risks and uncertainties, investors should not place undue reliance on forward-looking
statements as predictive of future results. We disclaim any obligation to update the
forward-looking statements made in this report. |
26
Item 3. Quantitative and Qualitative Disclosures about Market Risk.
Refer to the Companys Annual Report on Form 10-K for the year ended September 27, 2008 for a
complete discussion of our market risk. There have been no material changes in the current year
regarding this market risk information.
Item 4. Controls and Procedures.
(a) |
|
Disclosure Controls and Procedures.
Moog carried out an evaluation, under
the supervision and with the
participation of Company management,
including the Chief Executive Officer
and Chief Financial Officer, of the
effectiveness of the design and
operation of our disclosure controls
and procedures as defined in Exchange
Act Rules 13a-15(e) and 15d-15(e).
Based on that evaluation, the Chief
Executive Officer and Chief Financial
Officer concluded that these disclosure
controls and procedures are effective
as of the end of the period covered by
this report, to ensure that information
required to be disclosed in reports
filed or submitted under the Exchange
Act is made known to them on a timely
basis, and that these disclosure
controls and procedures are effective
to ensure such information is recorded,
processed, summarized and reported
within the time periods specified in
the Commissions rules and forms. |
|
(b) |
|
Changes in Internal Control over
Financial Reporting. There have been
no changes in our internal control over
financial reporting during the most
recent fiscal quarter that have
materially affected, or are reasonably
likely to materially affect, our
internal control over financial
reporting. |
PART II OTHER INFORMATION
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
(c) The following table summarizes our purchases of our common stock for the quarter ended December 27, 2008.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(c) Total |
|
|
(d) Maximum |
|
|
|
|
|
|
|
|
|
|
|
Number of |
|
|
Number (or |
|
|
|
|
|
|
|
|
|
|
|
Shares |
|
|
Approximate Dollar |
|
|
|
|
|
|
|
|
|
|
|
Purchased |
|
|
Value) |
|
|
|
(a) Total |
|
|
|
|
|
|
As Part of |
|
|
of Shares that |
|
|
|
Number of |
|
|
|
|
|
|
Publicly |
|
|
May Yet Be |
|
|
|
Shares |
|
|
(b) Average |
|
|
Announced |
|
|
Purchased Under |
|
|
|
Purchased |
|
|
Price Paid |
|
|
Plans or |
|
|
the Plans or |
|
Period |
|
(1)(2)(3) |
|
|
Per Share |
|
|
Programs (3) |
|
|
Programs (3) |
|
|
September 29 October 31, 2008 |
|
|
5,800 |
|
|
$ |
45.04 |
|
|
|
- |
|
|
|
1,000,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
November 1 30, 2008 |
|
|
224,688 |
|
|
$ |
30.67 |
|
|
|
213,600 |
|
|
|
786,400 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 1 27, 2008 |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
786,400 |
|
|
Total |
|
|
230,488 |
|
|
$ |
31.03 |
|
|
|
213,600 |
|
|
|
786,400 |
|
|
|
|
|
(1) |
|
Purchases in October consist of 5,800 shares of Class B common stock from the Moog family at $45.04 per share. |
|
(2) |
|
In connection with the exercise and vesting of stock options, we accept, from time to time, delivery of shares to pay the exercise price of
employee stock options. During November, we accepted the delivery of 11,088 shares at $34.15 per share in connection with the exercise of stock
options. |
|
(3) |
|
In October 2008, the Board of Directors authorized a share repurchase program. The program permits the purchase of up to 1,000,000 Class A or Class
B common shares in open market or privately negotiated transactions at the discretion of management. The transactions will be made in accordance
with rules and regulations of the U.S. Securities and Exchange Commission and other rules that govern such purchases. During November, we purchased
213,600 Class A shares at an average price $30.49 per share. The approximate dollar value of the maximum number of shares that may yet be purchased
as determined by the Class A Stock price on the last day of the quarter is $27 million. |
|
31.1 |
|
Certification of Chief Executive Officer pursuant to Exchange Act Rule 13a-14(a) as adopted pursuant to Section 302 of
the Sarbanes-Oxley Act of 2002. |
|
|
31.2 |
|
Certification of Chief Financial Officer pursuant to Exchange Act Rule 13a-14(a) as adopted pursuant to Section 302 of
the Sarbanes-Oxley Act of 2002. |
|
|
32.1 |
|
Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
27
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Moog Inc.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Registrant) |
|
|
|
|
|
|
|
|
|
Date: February 4, 2009
|
|
By
|
|
/s/Robert T. Brady |
|
|
|
|
|
|
|
|
|
|
|
|
|
Robert T. Brady |
|
|
|
|
|
|
Chairman |
|
|
|
|
|
|
Chief Executive Officer |
|
|
|
|
|
|
(Principal Executive Officer) |
|
|
|
|
|
|
|
|
|
Date: February 4, 2009
|
|
By
|
|
/s/John R. Scannell |
|
|
|
|
|
|
|
|
|
|
|
|
|
John R. Scannell |
|
|
|
|
|
|
Vice President |
|
|
|
|
|
|
Chief Financial Officer |
|
|
|
|
|
|
(Principal Financial Officer) |
|
|
|
|
|
|
|
|
|
Date: February 4, 2009
|
|
By
|
|
/s/Donald R. Fishback |
|
|
|
|
|
|
|
|
|
|
|
|
|
Donald R. Fishback |
|
|
|
|
|
|
Vice President - Finance |
|
|
|
|
|
|
|
|
|
Date: February 4, 2009
|
|
By
|
|
/s/Jennifer Walter |
|
|
|
|
|
|
|
|
|
|
|
|
|
Jennifer Walter |
|
|
|
|
|
|
Controller |
|
|
|
|
|
|
(Principal Accounting Officer) |
|
|
28
|
|
|
Exhibits |
|
|
Description |
|
|
|
|
|
|
31.1
|
|
Certification of Chief Executive Officer pursuant to Exchange Act Rule 13a-14(a) as adopted pursuant to Section 302 of
the Sarbanes-Oxley Act of 2002. |
|
|
|
31.2
|
|
Certification of Chief Financial Officer pursuant to Exchange Act Rule 13a-14(a) as adopted pursuant to Section 302 of
the Sarbanes-Oxley Act of 2002. |
|
|
|
32.1
|
|
Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
29